Bertil Lindahl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5169607/publications.pdf

Version: 2024-02-01

168 papers 16,015 citations

44069 48 h-index 123 g-index

169 all docs

169 docs citations

169 times ranked 17602 citing authors

#	Article	IF	CITATIONS
1	Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry. Clinical Research in Cardiology, 2023, 112, 68-74.	3.3	3
2	The ratio of cardiac troponin T to troponin I may indicate non-necrotic troponin release among COVID-19 patients. Clinica Chimica Acta, 2022, 527, 33-37.	1.1	7
3	Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death. Current Research in Translational Medicine, 2022, 70, 103323.	1.8	4
4	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. The Lancet Digital Health, 2022, 4, e37-e45.	12.3	16
5	Blood and imaging biomarkers in type 2 myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 269-271.	1.0	1
6	Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study. Journal of the American Heart Association, 2022, 11, e023079.	3.7	23
7	Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry. EuroIntervention, 2022, 18, 582-589.	3.2	8
8	The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction – from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC). Biomarkers, 2022, 27, 407-417.	1.9	3
9	Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration. American Journal of Epidemiology, 2022, 191, 1652-1665.	3.4	10
10	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. American Heart Journal, 2021, 231, 96-104.	2.7	49
11	ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. European Heart Journal, 2021, 42, 2260-2264.	2.2	23
12	Cardiovascular biomarkers in patients with COVID-19. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 310-319.	1.0	44
13	Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart, 2021, 107, 1145-1151.	2.9	15
14	Routine Oxygen Therapy Does Not Improve Health-Related Quality of Life in Patients With Acute Myocardial Infarction—Insights From the Randomized DETO2X-AMI Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 638829.	2.4	6
15	Sex-differences in circulating biomarkers during acute myocardial infarction: An analysis from the SWEDEHEART registry. PLoS ONE, 2021, 16, e0249830.	2.5	12
16	Sex differences in investigations and outcomes among patients with type 2 myocardial infarction. Heart, 2021, 107, 1480-1486.	2.9	9
17	Prognostic Utility of a Modified HEART Score When Different Troponin Cut Points Are Used. Critical Pathways in Cardiology, 2021, 20, 134-139.	0.5	2
18	The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). European Heart Journal Quality of Care & Dinical Outcomes, 2021, 7, 431-437.	4.0	15

#	Article	IF	CITATIONS
19	Clinical and prognostic implications of Câ€reactive protein levels in myocardial infarction with nonobstructive coronary arteries. Clinical Cardiology, 2021, 44, 1019-1027.	1.8	7
20	Predicting outcome in acute myocardial infarction: an analysis investigating 175 circulating biomarkers. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 806-812.	1.0	7
21	Non-employment and low educational level as risk factors for inequitable treatment and mortality in heart failure: a population-based cohort study of register data. BMC Public Health, 2021, 21, 1040.	2.9	5
22	Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex-related outcomes from DETO2X-AMI. American Heart Journal, 2021, 237, 13-24.	2.7	2
23	Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 353-360.	1.2	2
24	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. Circulation, 2021, 144, 773-787.	1.6	25
25	Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clinical Biochemistry, 2021, 98, 17-23.	1.9	15
26	The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial. American Journal of Preventive Cardiology, 2021, 7, 100199.	3.0	21
27	OUP accepted manuscript. Clinical Chemistry, 2021, 67, 1732-1734.	3.2	1
28	Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal, 2021, 42, 243-252.	2.2	84
29	Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments. Journal of Clinical Medicine, 2021, 10, 106.	2.4	7
30	Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment for Post Infarct Angina in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries: A MINOCA-BAT Sub Study Rationale and Design. Frontiers in Cardiovascular Medicine, 2021, 8, 717526.	2.4	3
31	Clinical risk scores identify more patients at risk for cardiovascular events within 30 days as compared to standard ACS risk criteria: the WESTCOR study. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 287-301.	1.0	6
32	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 343-355.	1.0	9
33	Myocardial infarction after elective percutaneous coronary intervention—which cardiac troponin cut-off to use?. European Heart Journal, 2021, , .	2.2	1
34	Survival in Patients With Suspected Myocardial Infarction With Nonobstructive Coronary Arteries: A Comprehensive Systematic Review and Meta-Analysis From the MINOCA Global Collaboration. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007880.	2.2	45
35	Avoiding Routine Oxygen Therapy in Patients With Myocardial Infarction Saves Significant Expenditure for the Health Care System—Insights From the Randomized DETO2X-AMI Trial. Frontiers in Public Health, 2021, 9, 711222.	2.7	0
36	Myocardial infarction with non-obstructive coronary artery disease. EuroIntervention, 2021, 17, e875-e887.	3.2	47

#	Article	IF	CITATIONS
37	Oxygen therapy in suspected acute myocardial infarction and concurrent normoxemic chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 984-992.	1.0	8
38	Statistics on mortality following acute myocardial infarction in 842 897 Europeans. Cardiovascular Research, 2020, 116, 149-157.	3.8	31
39	Effect of Oxygen Therapy on Cardiovascular Outcomes in Relation to Baseline Oxygen Saturation. JACC: Cardiovascular Interventions, 2020, 13, 502-513.	2.9	15
40	Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart, 2020, 106, 1812-1818.	2.9	40
41	A Possible Mechanism behind Faster Clearance and Higher Peak Concentrations of Cardiac Troponin I Compared with Troponin T in Acute Myocardial Infarction. Clinical Chemistry, 2020, 66, 333-341.	3.2	28
42	Novel clearance of muscle proteins by muscle cells. European Journal of Cell Biology, 2020, 99, 151127.	3.6	4
43	Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome. Circulation, 2020, 142, 1700-1708.	1.6	68
44	Sex-specific effects of implementing a high-sensitivity troponin I assay in patients with suspected acute coronary syndrome: results from SWEDEHEART registry. Scientific Reports, 2020, 10, 15227.	3.3	16
45	Effectiveness and Safety of the European Society of Cardiology 0-/1-h Troponin Rule-Out Protocol: The Design of the ESC-TROP Multicenter Implementation Study. Cardiology, 2020, 145, 685-692.	1.4	5
46	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	2.8	4
47	Application of the fourth universal definition of myocardial infarction in clinical practice. Biomarkers, 2020, 25, 322-330.	1.9	2
48	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	3.9	14
49	The Liver and Kidneys mediate clearance of cardiac troponin in the rat. Scientific Reports, 2020, 10, 6791.	3.3	34
50	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
51	Diagnosing type 2 myocardial infarction in clinical routine. A validation study. Scandinavian Cardiovascular Journal, 2019, 53, 259-265.	1.2	10
52	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care, 2019, 42, 2032-2041.	8.6	7
53	A Rule-Out Strategy Based on High-Sensitivity Troponin and HEART Score Reduces Hospital Admissions. Annals of Emergency Medicine, 2019, 73, 491-499.	0.6	38
54	Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design. Scandinavian Cardiovascular Journal, 2019, 53, 280-285.	1.2	9

#	Article	IF	CITATIONS
55	Circadian onset and prognosis of myocardial infarction with non-obstructive coronary arteries (MINOCA). PLoS ONE, 2019, 14, e0216073.	2.5	16
56	Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease. JRSM Cardiovascular Disease, 2019, 8, 204800401984197.	0.7	2
57	Symptoms Predictive of Acute Myocardial Infarction in the Troponin Era: Analysis From the TRAPID-AMI Study. Critical Pathways in Cardiology, 2019, 18, 10-15.	0.5	7
58	Sex differences in sickness absence and the morbidity-mortality paradox: a longitudinal study using Swedish administrative registers. BMJ Open, 2019, 9, e024098.	1.9	4
59	Do self-reported pregnancy complications add to risk evaluation in older women with established cardiovascular disease?. BMC Women's Health, 2019, 19, 160.	2.0	0
60	Sensitivity of undetectable level of high-sensitivity troponin T at presentation in a large non-ST-segment elevation myocardial infarction cohort of early presenters. International Journal of Cardiology, 2019, 284, 6-11.	1.7	10
61	Strong development of research based on national quality registries in Sweden. Upsala Journal of Medical Sciences, 2019, 124, 9-11.	0.9	3
62	Cardiac Troponin Elevation in PatientsÂWithout a Specific Diagnosis. Journal of the American College of Cardiology, 2019, 73, 1-9.	2.8	74
63	Reinfarction in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA): Coronary Findings and Prognosis. American Journal of Medicine, 2019, 132, 335-346.	1.5	45
64	Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. International Journal of Cardiology, 2019, 276, 261-267.	1.7	25
65	Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis. Clinical Research in Cardiology, 2019, 108, 749-762.	3.3	16
66	Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet, The, 2019, 393, 133-142.	13.7	142
67	Biobank linked to SWEDEHEART quality registryâ€"routine blood sample collection opens new opportunities for cardiovascular research. Upsala Journal of Medical Sciences, 2019, 124, 12-15.	0.9	3
68	Predictors of 10-year changes in levels of N-terminal pro B-type natriuretic peptide and cardiac troponin I in the elderly. International Journal of Cardiology, 2018, 257, 300-305.	1.7	9
69	Interphysician agreement on subclassification of myocardial infarction. Heart, 2018, 104, 1284-1291.	2.9	38
70	Myocardial Infarction with Nonobstructive Coronary Arteries: The Importance of Achieving Secondary Prevention Targets. American Journal of Medicine, 2018, 131, 524-531.e6.	1.5	13
71	How is cardiac troponin released from injured myocardium?. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 553-560.	1.0	179
72	Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries. American Heart Journal, 2018, 200, 60-66.	2.7	30

#	Article	IF	Citations
73	What to do when you question cardiac troponin values. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 577-586.	1.0	66
74	Use of copeptin for rapid rule-out of acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 570-576.	1.0	47
75	Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction. Circulation, 2018, 138, 2754-2762.	1.6	22
76	Christmas, national holidays, sport events, and time factors as triggers of acute myocardial infarction: SWEDEHEART observational study 1998-2013. BMJ: British Medical Journal, 2018, 363, k4811.	2.3	44
77	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. European Heart Journal, 2018, 39, 3766-3776.	2.2	112
78	Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. European Heart Journal, 2018, 39, 3780-3794.	2.2	78
79	High-Sensitivity Cardiac Troponin-Based Strategies for the Assessment of Chest Pain Patients—A Review of Validation and Clinical Implementation Studies. Clinical Chemistry, 2018, 64, 1572-1585.	3.2	22
80	Unrecognized myocardial infarction assessed by cardiac magnetic resonance imaging is associated with adverse long-term prognosis. PLoS ONE, 2018, 13, e0200381.	2.5	11
81	Possible mechanisms behind cardiac troponin elevations. Biomarkers, 2018, 23, 725-734.	1.9	95
82	Predictive Value of High-Sensitivity Troponin T for Systolic Dysfunction and Infarct Size (Six Months) After ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2018, 122, 735-743.	1.6	10
83	Oxygen therapy in ST-elevation myocardial infarction. European Heart Journal, 2018, 39, 2730-2739.	2.2	32
84	Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 321-328.	1.0	23
85	How to use D-dimer in acute cardiovascular care. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 69-80.	1.0	60
86	Editor's Choice-Rule-in of acute myocardial infarction: Focus on troponin. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 212-217.	1.0	32
87	Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 218-222.	1.0	70
88	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. Clinical Chemistry, 2017, 63, 542-551.	3.2	33
89	Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	64
90	Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation, 2017, 135, 1481-1489.	1.6	316

#	Article	IF	Citations
91	A Oâ€Hour/1â€Hour Protocol for Safe, Early Discharge of Chest Pain Patients. Academic Emergency Medicine, 2017, 24, 983-992.	1.8	26
92	Cardiac Troponins and Their Prognostic Importance in Patients with Suspected Acute Coronary Syndrome and Renal Dysfunction. Clinical Chemistry, 2017, 63, 1409-1417.	3.2	11
93	Impact of Sex on Cardiac Troponin Concentrations—A Critical Appraisal. Clinical Chemistry, 2017, 63, 1457-1464.	3.2	40
94	Î ² -Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. Journal of the American College of Cardiology, 2017, 69, 2710-2720.	2.8	174
95	The Reply. American Journal of Medicine, 2017, 130, e417-e418.	1.5	0
96	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	2.2	50
97	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. European Heart Journal, 2017, 38, 3056-3065.	2.2	302
98	Response by Lindahl et al to Letter Regarding Article, "Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease― Circulation, 2017, 136, 1082-1083.	1.6	2
99	Quantitation of 87 Proteins by nLC-MRM/MS in Human Plasma: Workflow for Large-Scale Analysis of Biobank Samples. Journal of Proteome Research, 2017, 16, 3242-3254.	3.7	10
100	Unstable Angina in the Era of Cardiac Troponin Assays with Improved Sensitivity—A Clinical Dilemma. American Journal of Medicine, 2017, 130, 1423-1430.e5.	1.5	44
101	Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry. Journal of the American Heart Association, 2017, 6, .	3.7	134
102	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. Upsala Journal of Medical Sciences, 2017, 122, 224-233.	0.9	15
103	Oxygen Therapy in Suspected Acute Myocardial Infarction. New England Journal of Medicine, 2017, 377, 1240-1249.	27.0	276
104	Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. PLoS ONE, 2017, 12, e0187662.	2.5	48
105	Unrecognized Myocardial Infarction Assessed by Cardiac Magnetic Resonance Imaging – Prognostic Implications. PLoS ONE, 2016, 11, e0148803.	2.5	14
106	The Use of Very Low Concentrations of Highâ€sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. Academic Emergency Medicine, 2016, 23, 1004-1013.	1.8	64
107	A 1-h Combination Algorithm Allows FastÂRule-Out and Rule-In of MajorÂAdverse Cardiac Events. Journal of the American College of Cardiology, 2016, 67, 1531-1540.	2.8	102
108	In reply:. Annals of Emergency Medicine, 2016, 67, 794-795.	0.6	0

#	Article	IF	CITATIONS
109	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet, The, 2016, 388, 1903-1911.	13.7	68
110	NT-proBNP is a powerful predictor for incident atrial fibrillation â€" Validation of a multimarker approach. International Journal of Cardiology, 2016, 223, 74-81.	1.7	42
111	The applied statistical approach highly influences the 99th percentile of cardiac troponin I. Clinical Biochemistry, 2016, 49, 1109-1112.	1.9	62
112	Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events. Annals of Emergency Medicine, 2016, 68, 649-658.e3.	0.6	28
113	Prognostic Importance of Sex-Specific Cardiac Troponin T 99th Percentiles in Suspected Acute Coronary Syndrome. American Journal of Medicine, 2016, 129, 880.e1-880.e12.	1.5	27
114	Periodontitis Increases the Risk of a First Myocardial Infarction. Circulation, 2016, 133, 576-583.	1.6	200
115	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Annals of Emergency Medicine, 2016, 68, 76-87.e4.	0.6	294
116	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. Clinical Chemistry, 2016, 62, 485-493.	3.2	17
117	The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 25-32.	1.2	14
118	Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. Journal of Epidemiology and Community Health, 2016, 70, 97-103.	3.7	16
119	Unrecognized myocardial infarctions detected by cardiac magnetic resonance imaging are associated with cardiac troponin I levels. Clinica Chimica Acta, 2016, 455, 189-194.	1.1	4
120	Increased risk of heart failure in women with symptoms of sleep-disordered breathing. Sleep Medicine, 2016, 17, 32-37.	1.6	20
121	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC: Cardiovascular Interventions, 2016, 9, 207-215.	2.9	43
122	Impact on Long-Term Mortality of Presence of Obstructive Coronary Artery Disease and Classification of Myocardial Infarction. American Journal of Medicine, 2016, 129, 398-406.	1.5	69
123	Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T $\hat{a} \in$ "Sub-analysis from the TRAPID-AMI study. International Journal of Cardiology, 2016, 209, 26-33.	1.7	101
124	Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry. European Journal of Preventive Cardiology, 2016, 23, 340-348.	1.8	58
125	Cardiac Biomarkers. Disease Markers, 2015, 2015, 1-3.	1.3	11
126	Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 312-318.	1.6	8

#	Article	IF	CITATIONS
127	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	3.2	37
128	Type 2 myocardial infarction: the chimaera of cardiology?. Heart, 2015, 101, 1697-1703.	2.9	40
129	Elevation of cardiac troponins measured after recreational resistance training. Clinical Biochemistry, 2015, 48, 803-806.	1.9	16
130	Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis, 2015, 242, 205-210.	0.8	108
131	Response to Letter Regarding Article, "Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction― Circulation, 2015, 131, e423.	1.6	0
132	βâ€Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study. Journal of the American Heart Association, 2015, 4, .	3.7	46
133	Implications of Introducing High-Sensitivity Cardiac Troponin T IntoÂClinical Practice. Journal of the American College of Cardiology, 2015, 65, 1655-1664.	2.8	67
134	Two-hour diagnostic algorithms for early assessment of patients with acute chest pain $\hat{a} \in \mathbb{C}^n$ Implications of lowering the cardiac troponin I cut-off to the 97.5th percentile. Clinica Chimica Acta, 2015, 445, 19-24.	1.1	12
135	Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke, 2015, 46, 3340-3347.	2.0	71
136	Unrecognized myocardial infarctions assessed by cardiovascular magnetic resonance are associated with the severity of the stenosis in the supplying coronary artery. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 98.	3.3	10
137	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clinical Biochemistry, 2015, 48, 201-203.	1.9	224
138	Type 2 myocardial infarction in clinical practice. Heart, 2015, 101, 101-106.	2.9	172
139	Influence of health-related quality of life on time from symptom onset to hospital arrival and the risk of readmission in patients with myocardial infarction. Open Heart, 2014, 1, e000051.	2.3	4
140	Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart, 2014, 1, e000002.	2.3	56
141	Cardiac Troponin I Associated with the Development of Unrecognized Myocardial Infarctions Detected with MRI. Clinical Chemistry, 2014, 60, 1327-1335.	3.2	9
142	DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. American Heart Journal, 2014, 167, 322-328.	2.7	56
143	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. American Journal of Cardiology, 2014, 113, 17-22.	1.6	10
144	In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 313-316.	1.0	30

#	Article	IF	CITATIONS
145	Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction. Circulation, 2014, 130, 325-332.	1.6	59
146	Revision of the Troponin T Release Mechanism from Damaged Human Myocardium. Clinical Chemistry, 2014, 60, 1098-1104.	3.2	51
147	Cardiac troponin I levels in patients with non–ST-elevation acute coronary syndrome—The importance of gender. American Heart Journal, 2014, 168, 317-324.e1.	2.7	44
148	Cardiac Troponin I Levels Measured With a High-Sensitive Assay Increase Over Time and Are Strong Predictors of Mortality in an Elderly Population. Journal of the American College of Cardiology, 2013, 61, 1906-1913.	2.8	111
149	High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. American Heart Journal, 2013, 166, 541-548.e1.	2.7	50
150	Small Changes in Troponin T Levels Are Common in Patients With Non–ST-Segment Elevation Myocardial Infarction and Are Linked to Higher Mortality. Journal of the American College of Cardiology, 2013, 62, 1231-1238.	2.8	88
151	Short- and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease. Clinica Chimica Acta, 2013, 422, 15-20.	1.1	14
152	Short- and Long-term Individual Variation in Cardiac Troponin in Patients with Stable Coronary Artery Disease. Clinical Chemistry, 2013, 59, 401-409.	3.2	66
153	The Story of Growth Differentiation Factor 15: Another Piece of the Puzzle. Clinical Chemistry, 2013, 59, 1550-1552.	3.2	44
154	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
155	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
156	Why all the struggle about CK-MB and PCI?. European Heart Journal, 2012, 33, 1046-1048.	2.2	36
157	Are There Really Biomarkers of Vulnerable Plaque?. Clinical Chemistry, 2012, 58, 151-153.	3.2	7
158	Unrecognized myocardial scars detected by delayed–enhanced MRI are associated with increased levels of NT-proBNP. Coronary Artery Disease, 2011, 22, 158-164.	0.7	5
159	Autoantibodies to cardiac troponin in acute coronary syndromes. Clinica Chimica Acta, 2010, 411, 1793-1798.	1.1	21
160	The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. American Heart Journal, 2010, 160, 224-229.	2.7	92
161	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	2.2	533
162	The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart, 2010, 96, 1617-1621.	2.9	537

#	ARTICLE	IF	CITATION
163	Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality. Circulation, 2007, 116, 1907-1914.	1.6	136
164	Diagnosis and Management of Patients with Suspected Acute Myocardial Infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 93-98.	1.2	2
165	Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non–ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2005, 45, 533-541.	2.8	115
166	The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: The FRISC II invasive troponin T electrocardiogram substudy. American Heart Journal, 2002, 143, 760-767.	2.7	121
167	New Generation Cardiac Troponin I Assay for the Access Immunoassay System. Clinical Chemistry, 2001, 47, 959-961.	3.2	40
168	Therapeutic implications of the use of cardiac markers in acute coronary syndromes. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 43-49.	1.2	2